PM360 2022 Trailblazer Awards Consumer Website/Online Initiative Silver Winner Avadel Pharmaceuticals and Fingerpaint

Narcolepsy Disrupts™ (Avadel Pharmaceuticals and Fingerpaint)

Because narcolepsy affects daily activities such as school, work, family relationships, or social interactions, it is understandable that HCPs and patients mainly talk about the daytime effects of the condition. However, narcolepsy is a chronic, lifelong, 24/7 condition involving disordered sleep cycles. Treatment, while often helpful, can also add burden to a patient’s life as some medications currently require patients to take doses in the middle of the night.

Fingerpaint’s Narcolepsy Disrupts campaign explores the “swirl” that narcolepsy patients live with. It reveals ways patients juggle symptoms and treatment—all day and all night. The swirl is constant and overwhelming.

The impact was far-reaching. The initial HCP display campaign earned 744,038 impressions with a click-through rate of 0.20%—double the industry benchmark. The patient campaign saw over two million impressions and a click-through rate four times the industry benchmark. Since launch, it has reached almost 639,000 users on Facebook.

Ads

You May Also Like

Healthcare Watch September 2022

Doctor Docs: Doctors Left Concerned After Roe v. Wade Overturn A recent Sermo study ...

Roadmap to Improved Coverage and Access for Specialty Products

As specialty pharmaceutical products are becoming increasingly complex due to more technology-driven drug development, ...

ELITE 2022 Tech-know Geek Chris Mutkoski of Axon Communications

Chris Mutkoski President, Axon Communications Board Member, Relevate Health Prescription Strength Communication With a ...